BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Explainers
      • Bharat Biotech's COVID-19 Vaccine...
      Explainers

      Bharat Biotech's COVID-19 Vaccine Covaxin Begins Phase-III Trials

      Covaxin, India's indigenous COVID-19 vaccine, has entered the phase three trials according to Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech.

      By - BOOM |
      Published -  17 Nov 2020 5:01 PM IST
    • Boomlive
      Bharat Biotechs COVID-19 Vaccine Covaxin Begins Phase-III Trials

      Covaxin, India's indigenous COVID-19 vaccine, has entered the phase three trials according to Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech. Covaxin is being developed by the Hyderabad-based Bharat Biotech in partnership with the Indian Council of Medical Research (ICMR).

      Speaking at a virtual conference organised by the Indian School of Business, Dr Ella told BOOM's Govindraj Ethiraj, "When the pandemic came, we partnered with ICMR for Covaxin. Covaxin has now entered the phase three trials." Dr Ella added that the vaccine is being developed in it's BSL3 (Biosafety level 3) production facility.

      In October, Bharat Biotech had received the Drugs Controller General of India (DCGI's) Subject Expert Committee (SEC) permission to conduct phase three trials of Covaxin after assessing data from the phase one and two trials.

      Elaborating on it's efforts to find a vaccine, Dr Ella also revealed Bharat Biotech's plans on developing a nasal vaccine along the lines of it's rotavirus gastroenteritis vaccine, ROTAVAC.

      "Our Covaxin production capacity is limited. But we are coming up with a different strategy using nasal drops which will be easier to deliver. Even the aanganwaadi worker in a village can deliver the vaccine," Dr Ella said.

      "It (Covaxin) is a two-dose injectable vaccine. However, I'm not happy because if we want to vaccinate 1.3 billion people, we'll need 2.6 billion doses. We are also working on a single-dose vaccine which will be given through nasal drops. We have experience creating Rotavirus vaccine as a two-drop concept which is what we want to bring to the COVID-19 vaccine. My feeling is that we can reach 1.3 billion people by next year," he added said.

      In September, Bharat Biotech had announced a licensing agreement with Washington University School of Medicine in St. Louis for a "novel chimp-adenovirus, single dose intranasal vaccine" for COVID-19.

      Dr Ella also called on diplomatic support to ensure Indian vaccines and expertise can be shared with other countries. "We can partner with Bangladesh, Pakistan and African countries and also partner with domestic manufacturers to produce the vaccine so that the countries can be self-sustainable," he said.

      Tags

      CovaxinBharat BiotechDr Krishna EllaICMRIndian Council of Medical ResearchNasal vaccineinjectable vaccineVaccine developmentCOVID-19
      Read Full Article
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!